ST中珠(600568) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 117,820,377.20, representing a decrease of 3.82% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 27,828,721.13, a significant decline of 577.44% year-on-year[5]. - Basic and diluted earnings per share were both CNY -0.0140, reflecting a decrease of 566.67% compared to the same period last year[6]. - Total operating revenue for Q1 2023 was ¥117,820,377.20, a decrease of 3.5% compared to ¥122,493,820.06 in Q1 2022[20]. - Net profit for Q1 2023 was a loss of ¥21,844,934.44, compared to a profit of ¥1,621,721.13 in Q1 2022[21]. - The total comprehensive loss for Q1 2023 was ¥21,955,975.58, compared to a comprehensive income of ¥1,622,794.27 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY 55,884,126.32, down 71.31% from the previous year[5]. - Cash flow from operating activities increased significantly to ¥153,428,109.94 in Q1 2023, compared to ¥97,155,935.90 in Q1 2022, representing a growth of 57.9%[24]. - The net cash flow from operating activities was -$55.88 million, compared to -$32.62 million in the previous year, indicating a decline in operational performance[25]. - Cash and cash equivalents were reported at RMB 515,850,737.83, a decrease from RMB 577,180,844.05, reflecting a decline of approximately 10.65%[17]. - Cash and cash equivalents at the end of the period totaled $331.13 million, down from $562.68 million at the end of the previous year[26]. - The net increase in cash and cash equivalents was -$62.80 million, contrasting with a positive increase of $35.34 million in the previous year[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,640,085,392.25, a decrease of 1.96% from the end of the previous year[6]. - The company's current assets totaled RMB 1,771,922,816.09, down from RMB 1,839,334,761.76, indicating a decrease of about 3.67%[18]. - The company's total liabilities decreased to ¥725,342,877.67 in Q1 2023 from ¥775,972,082.61 in Q1 2022, a reduction of approximately 6.5%[20]. - The company's long-term equity investments stood at RMB 349,482,036.42, a minor decrease from RMB 352,514,093.13, representing a decline of approximately 0.91%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,739[13]. - The top shareholder, Shenzhen Landi Technology Development Co., Ltd., holds 19.08% of the shares, with 380,172,862 shares pledged[13]. Expenses and Costs - The company experienced a 31.38% increase in sales expenses, attributed to higher costs in the pharmaceutical sector[11]. - Total operating costs increased to ¥136,899,729.17 in Q1 2023, up 7.4% from ¥126,995,078.54 in Q1 2022[20]. - Research and development expenses rose to ¥4,555,699.77 in Q1 2023, up from ¥3,727,371.97 in Q1 2022, indicating an increase of 22.2%[21]. - Cash paid for purchasing goods and services was $51.50 million, down from $65.75 million in the previous year, indicating cost control measures[25]. - The company paid $61.32 million in employee compensation, an increase from $51.68 million in the previous year, reflecting higher labor costs[25]. Investment and Future Outlook - The company reported an investment loss of ¥1,065,207.38 in Q1 2023, compared to a gain of ¥1,473,744.90 in Q1 2022[21]. - The company has not disclosed any new product developments or technological advancements in the provided documents[16]. - There were no significant updates regarding market expansion or mergers and acquisitions mentioned in the conference call[16]. - The company has not provided specific future guidance or performance outlook in the available reports[16].